Zymeworks Inc (ZYME, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks Inc has a market cap of $1.75 billion; its shares were traded at around $38.55 with and P/S ratio of 22.53. GuruFocus has detected 2 severe warning signs with Zymeworks Inc. .
For the last quarter Zymeworks Inc reported a revenue of $1.88 million, compared with the revenue of $28.93 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $29.5 million, a decrease of 44.3% from the previous year. For the complete 30-year financial data, please go here.. For the last five years Zymeworks Inc had an average revenue growth rate of 82.3% a year.
The reported loss per diluted share was $3.83 for the year, compared with the loss per share of $1.7165 in the previous year. The Zymeworks Inc had an operating margin of -509.52%, compared with the operating margin of -62.48% a year before. The 10-year historical median operating margin of Zymeworks Inc is -206.63%. The profitability rank of the company is 1 (out of 10).
For the complete 20-year historical financial data of ZYME, click here.
